Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2102 in advanced cancers
NCT05735496Phase 1Active, not recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Mar 2023
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB2102 in solid tumor (advanced stage), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum tolerated dose at 21 days and 2 more. Started Mar 2023; status: active, not recruiting.
02
Drugs
TQB2102
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05735496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05735496.